Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

NCT02751385 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated- Study halted due to low recruitment.

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Microgynon
DRUG: Nintedanib

Sponsor

Boehringer Ingelheim